

Pyoderma Gangrenosum Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/P7F3B4DDAA94EN.html>

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: P7F3B4DDAA94EN

Abstracts

The 7 major pyoderma gangrenosum markets reached a value of US\$ 126.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 185.1 Million by 2034, exhibiting a growth rate (CAGR) of 3.53% during 2024-2034.

The pyoderma gangrenosum market has been comprehensively analyzed in IMARC's new report titled "Pyoderma Gangrenosum Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pyoderma gangrenosum is a rare and debilitating non-infectious skin disorder characterized by its distinctive ulcerative lesions. These ulcers are often painful and rapidly progressing, with undermined and purple- or blue-colored edges. Pyoderma gangrenosum is considered an autoimmune condition, where the immune system mistakenly attacks healthy skin tissue, leading to the development of these deep and necrotic ulcers. The symptoms of the ailment may begin as pustules or small nodules that quickly transform into painful ulcers. These ulcers can vary in size and often have a raised border with a necrotic center. Due to their aggressive nature, they can expand rapidly and cause significant tissue damage if not treated promptly. The diagnosis of pyoderma gangrenosum is typically made through clinical examination, a thorough evaluation of medical history, and the physical characteristics of the ulcers. Skin biopsies are also utilized to rule out various other conditions and provide insights into the inflammatory nature of the disease.

The increasing prevalence of immune system dysregulation or dysfunction, causing the body's defense mechanisms to attack healthy tissues, is primarily driving the pyoderma gangrenosum market. In addition to this, the inflating utilization of effective therapeutic interventions, including immunosuppressive medications like corticosteroids,

cyclosporine, and biologics, aimed at managing the condition and averting exacerbations, is also creating a positive outlook for the market. Moreover, the widespread adoption of wound care strategies, given their pivotal role in promoting healing, reducing infection risk, and alleviating discomfort, is further bolstering the market growth. Apart from this, the rising usage of skin grafting procedures, which involve transplanting healthy skin to the ulcer site to facilitate recovery and minimize scarring, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of targeted therapies that aim to modulate specific immune responses responsible for disease pathogenesis is also augmenting the market growth. These agents hold the potential to address the underlying immunological dysregulation, thereby improving the quality of life for individuals suffering from the condition. Furthermore, the escalating application of adjunctive therapies like hyperbaric oxygen therapy, since they can speed up healing time in patients by enhancing oxygen supply to the affected tissues, is expected to drive the pyoderma gangrenosum market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the pyoderma gangrenosum market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pyoderma gangrenosum and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pyoderma gangrenosum market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pyoderma gangrenosum market
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the pyoderma gangrenosum market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current pyoderma gangrenosum marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report: Market Insights

How has the pyoderma gangrenosum market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the pyoderma gangrenosum market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the pyoderma gangrenosum market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of pyoderma gangrenosum across the seven major markets?

What is the number of prevalent cases (2018-2034) of pyoderma gangrenosum by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of pyoderma gangrenosum by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with pyoderma gangrenosum across the seven major markets?

What is the size of the pyoderma gangrenosum patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of pyoderma gangrenosum?

What will be the growth rate of patients across the seven major markets?

Pyoderma Gangrenosum: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for pyoderma gangrenosum drugs across the

seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pyoderma gangrenosum market?

What are the key regulatory events related to the pyoderma gangrenosum market?

What is the structure of clinical trial landscape by status related to the pyoderma gangrenosum market?

What is the structure of clinical trial landscape by phase related to the pyoderma gangrenosum market?

What is the structure of clinical trial landscape by route of administration related to the pyoderma gangrenosum market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PYODERMA GANGRENOSUM - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 PYODERMA GANGRENOSUM - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 PYODERMA GANGRENOSUM - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 PYODERMA GANGRENOSUM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PYODERMA GANGRENOSUM - UNMET NEEDS

10 PYODERMA GANGRENOSUM - KEY ENDPOINTS OF TREATMENT

11 PYODERMA GANGRENOSUM - MARKETED PRODUCTS

- 11.1 List of Pyoderma Gangrenosum Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 PYODERMA GANGRENOSUM - PIPELINE DRUGS

12.1 List of Pyoderma Gangrenosum Pipeline Drugs Across the Top 7 Markets

12.1.1 Adalimumab - AbbVie/AstraZeneca

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 IFX1 - InflaRx

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 Ixekizumab - Eli Lilly and Company

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. PYODERMA GANGRENOSUM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PYODERMA GANGRENOSUM – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 PYODERMA GANGRENOSUM - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Pyoderma Gangrenosum - Market Size

- 15.2.1.1 Market Size (2018-2023)
- 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Pyoderma Gangrenosum - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Pyoderma Gangrenosum - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Pyoderma Gangrenosum - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Pyoderma Gangrenosum - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Pyoderma Gangrenosum - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Pyoderma Gangrenosum - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Pyoderma Gangrenosum - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Pyoderma Gangrenosum - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Pyoderma Gangrenosum - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Pyoderma Gangrenosum - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Pyoderma Gangrenosum - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Pyoderma Gangrenosum - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Pyoderma Gangrenosum - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Pyoderma Gangrenosum - Market Size

- 15.7.1.1 Market Size (2018-2023)
- 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Pyoderma Gangrenosum - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Pyoderma Gangrenosum - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Pyoderma Gangrenosum - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Pyoderma Gangrenosum - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Pyoderma Gangrenosum - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Pyoderma Gangrenosum - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Pyoderma Gangrenosum - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Pyoderma Gangrenosum - Access and Reimbursement Overview

16 PYODERMA GANGRENOSUM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PYODERMA GANGRENOSUM MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 PYODERMA GANGRENOSUM MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Pyoderma Gangrenosum Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/P7F3B4DDAA94EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P7F3B4DDAA94EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

